Belite Bio, Inc. has completed rolling submission of its new drug application (NDA) to the FDA for tinlarebant, an investigational therapy for the treatment of Stargardt disease.
The update follows less than 3 months after the company kicked off the submission process.
First, let’s get a look at the therapy in question.
As a once-daily, orally-administered tablet, tinlarebant is formulated to intervene early and maintain retinal tissue health among patients with Stargardt disease type 1 (STGD1).
How it does this: By reducing toxic accumulation within the eye that leads to STGD1 development.
- Click here for a more detailed breakdown and description of the process.
Now to its NDA—or rather, its rolling submission process.
Considering we previously covered this topic, see here for our full rundown on what it entails (and how companies can qualify).
In the case of Belite’s tinlarebant: The oral tablet’s eligibility for this process can be traced back to its two FDA designations for its STGD1 indication (plus two others):
- Fast Track
- Breakthrough Therapy
- This also grants a company priority review eligibility and more frequent meetings with the federal agency.
And in the case of tinlarebant?
The tablet has received both Fast Track and Breakthrough Therapy (BTD) designations for its STGD1 indication.
- Its NDA package was submitted under BTD.
Regarding the contents of this submission: Phase 3 data from the global DRAGON trial is at the center. Check out the details of this study—plus its clinical findings from December 2025.
So! What happens now?
Per FDA protocol, Belite’s completed application will now undergo a 60-day review period with the federal agency.
A Prescription Drug User Fee Act (PDUFA) target action date will be assigned only if the FDA accepts the submission.
Will there be anything special about this PDUFA?
Based on tinlarebant’s multiple FDA designations, its priority review eligibility means the review period leading up to the PDUFA may only be 6 months (instead of the standard 10-month period).
Nice! And lastly: the big-picture.
The oral therapy has the potential to become the first-ever treatment approved by the FDA for Stargardt.